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ABSTRACT
Ryan J. Serra
Phenytoin and its Metabolite, 5-(p-Hydroxyphenyl-), 5-Phenylhydantoin, Decrease 
Supernatant Levels of Matrix-Metalloproteases in the Human Macrophage: Implications 
for Drug-Induced Gingival Overgrowth
(Under the Direction of Salvador Nares)
OBJECTIVES:  To evaluate the effects of Phenytoin (PHT) and its metabolite 5-(p-
Hydroxyphenyl-), 5-Phenylhydantoin (HPPH) on LPS-induced macrophage expression of 
MMP, TIMP, TNF-α, and IL-6. METHODS:  Human macrophages were pretreated with 
either: 1) 15µg/ml PHT, 2) 50µg/ml PHT, 3) 15µg/ml HPPH, or 4) 50µg/ml HPPH for 1 
hour, then challenged with 100ng/ml A. actinomycetemcomitans (A.a.) LPS.  Untreated 
cells served as control cultures.  Total RNA was extracted at 4 hours, and supernatants 
were collected at 24 hours. RESULTS:  A dose-dependent reduction of supernatant A.a.-
induced MMP-1, MMP-3, MMP-9, and TIMP-1 was noted upon pretreatment with PHT 
and HPPH.  A minimal effect was noted on gene expression for MMP-9 and TIMP-1. 
MMP2, MMP12, TIMP2-4 production does not appear to be influenced Aa LPS, PHT, or 
HPPH.  CONCLUSIONS:  A.a. LPS-induced macrophage expression of MMP-1, MMP-
3, MMP-9, and TIMP-1 is blunted by exposure to PHT and HPPH.
iv
ACKNOWLEDGEMENTS
“Next in importance to freedom and justice is popular education, without which neither 
freedom nor justice can be permanently maintained.”
James A. Garfield
This work represents the combined efforts of, not only myself, but a tremendously gifted 
and generous group of people around me, without whom, I could not have learned nor 
accomplished so much.  For this, I would like to express my sincere gratitude and 
appreciation for the time and effort that these people so generously gave on my behalf, so 
that I may succeed in my scholastic and professional investigations and endeavors.  
To my mentor, Salvador Nares, I hope that you know that I am greatly appreciative your 
wisdom, guidance, and commitment to excellence, not only through clinical education, 
but also in the development of a kindred intellect within the lab.  I learned a tremendous 
amount about this subject as well as the investigative process from your guidance, and 
will always respect you as a scientist, mentor, and colleague.
vTo the members of my committee, David Paquette and Sylvana Barros, for always 
making time to help guide me through this journey and lending your unique and poignant 
insights to this investigation.  
To Abdel-ghany Al-Saidi, whose help in the lab culturing monocytes and macrophages, 
as well as running the RT-PCR and ELISA assays, was indispensable in conducting this 
experiment.
To the rest of the laboratory group for their support.
To my program director David Paquette and the chair of the Department of 
Periodontology, Ray Williams for accepting me into the program for advanced training in 
periodontology as well as the degree program for a Master of Science in Periodontology. 
Your guidance and mentorship through this challenging process has been invaluable.
To my Father and Jen, whose encouragement and support through this journey have been 
indispensable.  Without a doubt, your espousal of my academic pursuits have certainly 
helped make this dream a reality.
vi
TABLE OF CONTENTS
Page
LIST OF FIGURES ......................................................................................................... viii
LIST OF ABBREVIATIONS............................................................................................ ix
Chapter
I A REVIEW OF PHENYTOIN INDUCED GINGIVAL OVERGROWTH AND 
THE ROLE OF THE MACROPHAGE .............................................................. 1
Pharmacology ............................................................................................. 2
Side Effects ................................................................................................. 3
Clinical and Histological Presentation........................................................ 4
Treatment of DIGO..................................................................................... 6
The Pathophysiology of DIGO and the Macrophage ................................. 8
Conclusion ................................................................................................ 15
II PHENYTOIN AND ITS METABOLITE, 5-(P-HYDROXYPHENYL-), 5-
PHENYLHYDANTOIN, DECREASE SUPERNATANT LEVELS OF 
MATRIX-METALLOPROTEASES IN THE HUMAN MACROPHAGE: 
IMPLICATIONS FOR DRUG-INDUCED GINGIVAL OVERGROWTH..... 17
vii
Introduction............................................................................................... 17
Materials and Methods.............................................................................. 19
Monocyte Isolation and Differentiation into Macrophages ........ 19
Macrophage Stimulation ............................................................. 20
Real Time-PCR ........................................................................... 21
MMP, TIMP Protein Assay......................................................... 22
Cytokine Assay............................................................................ 24
Cell Viability ............................................................................... 24
Statistics....................................................................................... 25
RESULTS ................................................................................................. 25
PHT and HPPH Inhibit LPS-Induced Supernatant Levels of 
MMP-1, MMP-2, MMP-3, MMP-9, and TIMP-1 in a Dose-
Dependent Manner ...................................................................... 25
Supernatant Levels of TNF-α but not IL-6 are Decreased in 
Response to PHT......................................................................... 26
PHT Inhibit LPS-Induced MMP-9 and TIMP-1 mRNA in a Dose-
Dependent Manner at 4 hours ..................................................... 27
DISCUSSION........................................................................................... 27
REFERENCES .................................................................................................. 48
viii
LIST OF FIGURES
FIGURE 1 ......................................................................................................................... 34
FIGURE 2 ......................................................................................................................... 35
FIGURE 3 ......................................................................................................................... 36
FIGURE 4 ......................................................................................................................... 37
FIGURE 5 ......................................................................................................................... 38
FIGURE 6 ......................................................................................................................... 39
FIGURE 7 ......................................................................................................................... 40
FIGURE 8 ......................................................................................................................... 41
FIGURE 9 ......................................................................................................................... 42
FIGURE 10 ....................................................................................................................... 43
FIGURE 11 ....................................................................................................................... 44
FIGURE 12 ....................................................................................................................... 45
FIGURE 13 ....................................................................................................................... 46
FIGURE 14 ....................................................................................................................... 47
ix
LIST OF ABBREVIATIONS
µg Microgram
µL Microliter
A.a. Aggregatibacter actinomycetemcomitans
bFGF Basic fibroblast growth factor
C Celsius
CsA Cyclosporine A
CD14+ Cluster of differentiation 14 positive
cDNA Complementary deoxyribonucleic acid
CO2 Carbon dioxide
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1
DIGO Drug induced gingival overgrowth
DMEM Dulbecco's Modified Eagle Medium
DMSO Dimethyl sulfoxide
ECM Extracellular matrix
ELISA Enzyme-linked immunosorbent assay
xFACS Fluorescence-activated cell sorting
FBS Fetal bovine serum
FDA United States Food and Drug Administration
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
GM-CSF Granulocyte-macrophage-colony stimulating factor
h Hour
HPPH Phenytoin metabolite (5-(p-hydroxyphenyl-), 5-phenylhydantoin)
ID Identification
IL Interleukin
INF-γ Interferon-gamma
L Liter
LPS Lipopolysaccharide
MAC Macrophage
mg Milligram
mL Milliliter
MMP Matrix metalloproteinase
MON Monocyte
xi
MTT 3-[4,5- diethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
Na+ Sodium
ng Nanograms
nm Nanometers
PDGF Platelet-derived growth factor
pg Picograms
PG Prostaglandin 
PHT Phenytoin
RNA Ribonucleic acid
RT-PCR Real-time polymerase chain reaction
TGF Transforming growth factor
TIMP Tissue inhibitor of metalloproteinase
TLR Toll-like receptor
TNF-α Tumor necrosis factor-alpha
xii
A REVIEW OF PHENYTOIN INDUCED GINGIVAL 
OVERGROWTH AND THE ROLE OF THE MACROPHAGE
Drug-induced gingival overgrowth (DIGO) is widely recognized as a common 
unwanted sequelae associated with a broad variety of medications prescribed to treat a litany 
of medical ailments. The American Academy of Periodontology classifies this as a “Drug 
influenced gingival enlargement” covered under the “Gingival diseases modified by 
medications” family (Armitage G, 1999).  Currently, over 20 classes of medications (Rees et 
al, 1995), prescribed to at least 5% of the elderly population (Lewis et al, 1993) are 
associated with DIGO. Among these, the most common classes of medications associated 
with DIGO include anti-epileptics [(carbamazepine (Tegretol), phenytoin (Dilantin), 
mephenytoin (Mesantoin)[, calcium channel blockers [amlodipine (Norvasc), diltiazem 
(Cardizem), nifedipine (Procardia)], and immunosuppressants [cyclosporine (Sandimmune)].  
The prevalence of DIGO varies among the classes of medications, with anti-epileptics 
producing clinically identifiable overgrowth in approximately 50% of patients, and calcium 
channel blockers and immunosuppressants contributing to gingival overgrowth in 6 – 25% of 
patients (Academy Report on Drug Induced Gingival Enlargement 2004, Neville et al, 2002).  
In addition, some reports have linked DIGO with erythromycin and certain oral 
contraceptives (Seymour et al, 2000).  
2To date, the pathological mechanisms associated with DIGO are not completely 
understood. Further, the etiology appears to be multifactorial in origin involving drug, host 
and microbial factors. The main target cell appears to be the fibroblast although other 
resident and infiltrating cells including the macrophage will be exposed and respond to these 
agents. Macrophages are differentiated monocytes with pivotal roles in many defensive and 
homeostatic responses. These cells migrate to and take up residence in virtually every tissue 
in the body. However, recent studies indicate that the macrophage may play a pivotal role in 
tissue fibrosis and DIGO. Here the current understanding regarding the role of the 
macrophage in phenytoin (PHT) associated gingival overgrowth is reviewed. 
Pharmacology
Phenytoin (5,5-diphenyl-2, 4-imidazolidinedione) is an antiepileptic medication, 
similar in chemical structure to barbiturates (Figure 1). First synthesized by the German 
chemist Heinrich Blitz in 1908, it was not introduced for public consumption until 1938 as an 
alternative to phenobarbital (Smith, 1992). This was, in large part, due to the fact that no 
practical application could be devised during that period of time.  Functionally, it acts to 
stabilize voltage gated sodium channels by increasing efflux or decreasing influx of sodium 
ions across cell membranes in the motor cortex during generation of nerve impulses 
(Goodman and Gillman, 2001).  This has the effect of reducing electrical conductance among 
brain cells, and cardiac muscles.  Phenytoin is commonly prescribed for the management of 
seizures, neuralgias, and cardiac arrhythmias, as it helps to dampen unwanted, runaway brain 
activity (Smith, 1992).  
3Phenytoin is metabolized in the liver via aromatic hydroxylation by the cytochrome 
P450 (CYP2C9 and CYP2C19) enzymes primarily to 5-(p-hydroxyphenyl-), 5-
phenylhydantoin (HPPH). This may be further metabolized to a catechol that spontaneously 
oxidizes to semiquinone and quinone species, which covalently modify proteins. The reactive 
intermediate, arene oxide is deactivated by either epoxide hydrolase to dihydrodiol or by the 
action of glutathione (GSH) and glutathione transferase (Cuttle et al, 2000). Phenytoin 
metabolism may also be affected by other drugs. For example, drugs that decrease serum 
levels of phenytoin include rifampin and phenobarbital while drugs that increase phenytoin 
levels include amiodarone, chloramphenicol, cimetidine, disulfiram, fluconazole, fluoxetine, 
isoniazid (INH), omeprazole, and paroxetine. The oral absorption of phenytoin can be 
reduced by antacids containing magnesium, calcium carbonate, or aluminum, calcium salts, 
or enteral feeding products (tube feedings) (Katzung, 2004). Thus, measuring serum levels of 
phenytoin may be necessary when patients begin or discontinue other medications.  
Side Effects
In February 2008, the United States Food and Drug Administration (FDA) announced 
an increased risk (2.1%) of suicidal behavior associated with patients taking certain anti-
epilipetics, such as phenytoin (Information for Healthcare Professionals Suicidality and 
Antiepileptic Drugs, FDA, 2008). This was based on 199 placebo-controlled studies 
involving 43,892 patients (27,863 treated patients versus 16,029 placebo patients). 
Furthermore, phenytoin use has been associated with certain blood dyscrasias, including 
neutropenia, leucopenia, thrombocytopenia, and anemia, as well as certain dermatologic 
4reactions, such as epidermal necrolysis and Stevens-Johnson syndromes.  Limited oral side 
effects are known (Katzung, 2004, Lexicomp, 2009).  Special care should be taken when 
sedating patients taking phenytoin, as the sedative effects may be potentiated. If 
discontinuation of phenytoin is indicated, this should not be done abruptly because of the 
possibility of increasing seizure frequency. 
Clinical and Histological Presentation
In the oral cavity, phenytoin has long been recognized as one of the most identifiable 
precipitating medications for DIGO, as the first reported case was described by Kimball in 
1939. Phenytoin associated DIGO typically appears within 1 to 3 months following initiation 
of pharmacotherapy, and typically begins with the enlargement of the anterior labial papillae 
(Cohen, 2007). This overgrowth often extends facially, lingually and coronally and may 
result in malpositioning of teeth, esthetic disfigurement and interference in hygiene, 
mastication and speech (Hallmon, 1999).  Expansion of the gingival overgrowth may reach 
its maximum level after 12 – 18 months (Brown et al, 1991). Gingival lobulations may 
appear fibrotic or inflamed in nature depending on the amount of plaque induced gingival 
inflammation (Figure 2A and B). Clinically, most DIGOs appear to be indistinguishable from 
one drug to the other with the exception of phenobarbitone and cyclosporine. Phenobarbitone 
generally produces a uniform enlargement of the gingival tissue without lobulation, which 
tends to be greater in the posterior. Cyclosporine on the other hand, may produce lobulations 
that appear pebbly in texture (Gregoriou et al, 1996) (Figure 3). These tissues have also been 
associated with common fungal Candidal superinfections, and the tissue tends to be more 
5hyperemic in nature than phenytoin induced gingival overgrowth (Academy Report on Drug 
Induced Gingival Enlargement, 2004). DIGO may further be classified by its level of 
severity. Aas et al (1963) developed a semiquantitative index for describing DIGO based 
upon the papillary and gingival structures involved, as well as the amount of coronal tooth 
structure being covered.  This index  classifies no overgrowth as 0,  blunting of the gingival 
margin (mild gingival overgrowth) as 1, moderate gingival overgrowth (less than one-third of 
the crown length) as 2, and severe gingival overgrowth (more than one-third of the crown 
length) as 3. 
Histologically, DIGO appears as an excessive accumulation of extracellular matrix 
proteins with varying degrees of inflammatory infiltrate present. The epithelium of involved 
gingival tissues demonstrates stratified squamous epithelium with elongated rete ridges that 
extend deep into the connective tissue (Figure 4A and B). Interestingly, there is considerable 
similarity in the histologic presentation of phenytoin-induced gingival overgrowth and that 
associated with calcium channel blockers or immunosuppressants suggesting a common 
mechanism underlying the pathophysiology of DIGO (Miranda et al, 2001). The degree of 
inflammatory infiltrate and fibrosis appears to be affected by the quality of oral hygiene and 
individual susceptibility, stemming from genetic, behavioral and environmental factors. 
Indeed, the importance of plaque as a cofactor has been recognized by the American 
Academy of Periodontology (AAP) which classifies this as gingival inflammation being 
modified by a medication (Academy Report on Drug Induced Gingival Enlargement 2004, 
Ellis et al, 1999, Armitage, 1999). Furthermore, it has been demonstrated that patients with 
pre-existing gingival inflammation prior to drug administration are more likely to develop 
DIGO (Varga et al, 1998). Additional factors associated with DIGO include age (inverse 
6relationship), gender (males are 3 times more likely to develop DIGO), concomitant 
medication use, genetic factors, and other periodontal variables that pertain to the 
development and control of local inflammation (Seymour et al, 2000). Simultaneous 
administration of phenytoin with cyclosporine or calcium channel blockers does not appear 
to affect the degree of gingival inflammation.
Treatment of DIGO
The first phase of treatment generally involves discontinuation and substitution of the 
offending medication by the prescribing physician. Substitutes nonetheless, may induce 
DIGO to a different degree. For example, valproic acid, has been associated with reduced 
incidence but not elimination of DIGO (Tan et al, 2004). If the use of PHT is mandatory, 
professional scaling and root planing, frequent reevaluation, and impeccable home care is 
necessary to help minimize the severity of DIGO (Somacarrera et al, 1997). Furthermore, 
concomitant treatment with phenytoin and other anti-epileptics does not appear to influence 
the extent or incidence of DIGO. This suggests that chronic co-medication with other anti-
convulsants known to induce phenytoin metabolism, does not affect plasma or saliva HPPH 
steady-state levels, nor the degree of gingival overgrowth in adult epileptic patients (Kamali 
et al, 1999). Pharmacologic substitution has also been noted to be a successful treatment 
modality for other medications, such as azothioprine or tacrolimus for cyclosporine (Nam et 
al, 2008).
Plaque scores and gingival inflammation appear to exacerbate the expression of drug-
induced gingival overgrowth, irrespective of the initiating drug (Seymour et al, 2000). Such a 
7finding confirms plaque biofilm as a significant risk factor for the expression of DIGO (Ellis 
et al. 1999; King et al. 1993; Pernu et al. 1992; Somacarrera et al. 1994; Thomason et al. 
1995; Thomason et al. 1996; Thomason et al. 1993).  Accordingly, factors that impede oral 
hygiene measures such as orthodontic appliances, may negatively impact plaque control and 
exacerbate the prevalence and severity of overgrowth (Daley et al. 1991).  Therefore, 
mechanical therapy such as scaling and root planning, combined with proper home 
maintenance is of paramount importance.  Chemotherapeutic plaque control measures, 
including chlorhexidine mouthrinses are often beneficial in preventing plaque buildup while 
short term resolution has been reported following a course of metronidazole and 
azithromycin, although the mechanism behind this is not entirely understood.  The overall 
duration of the effect of azithromycin treatment has been reported to range between 3 months 
and two years, even though this has not been substantiated through rigorous testing 
(Strachan, 2003). Topical anti-fungal medication has also been demonstrated to produce 
improvement in the clinical presentation of DIGO. However, resolution may take anywhere 
from 1 to 8 weeks (Khocht et al, 1997).  
If non-surgical interventions are unsuccessful, gingival excess may be removed via a 
scalpel or laser. While surgical resection by an external bevel or internal bevel incision using 
a scalpel blade remains the standard in the treatment of exuberant cases of DIGO (Rostocket 
al. 1986), some studies have demonstrated advantages to the use of laser resection. These 
include sterilization of the surgical field, reduced hemorrhage during excision, and reduced 
postoperative discomfort (Pick & Colvard 1993, Romanos & Nentwig1996, Seymour et al, 
2000). Furthermore, a decrease in the recurrence of DIGO in tissues treated with lasers 
compared to traditional external- and internal bevel approaches after 6 months has been 
8reported (Mavrogiannis et al, 2006).  Since cellular mitotic activity starts from within the 
gingival connective tissue following flap surgery, one possible explanation for this finding 
may be that more time is required for gingival enlargement to manifest itself clinically as a 
result of the decrease in collagen production by gingival fibroblasts or by delayed wound 
healing capabilities of tissues (Abergel et al. 1984a, b). Unfortunately, recurrence of gingival 
overgrowth will often require additional surgical intervention. In the presence of adequate 
periodontal maintenance, recurrence of DIGO appears to be around 40% in patients taking 
cyclosporine with higher incidence being associated with younger age, poor hygiene and 
gingival inflammation. Of note, rinsing with chlorhexidine twice per day has been reported to 
reduce or eliminate recurrence (Academy Report on Drug-Induced Gingival Enlargement 
2004). 
The Pathophysiology of DIGO and the Macrophage
Although the pathogenesis of phenytoin-induced gingival overgrowth is not clearly 
understood, numerous theories have been proposed to account for the disruption of 
extracellular matrix (ECM) homeostasis. It is widely recognized that fibroblasts are largely 
responsible for the maintenance of connective tissue homeostasis in human gingival tissues 
(Everts et al, 1996; Yamada et al, 2000) via an intracellular pathway involving phagocytosis 
of collagen and by an extracellular pathway that includes secretion of matrix-degradating 
enzymes, the matrix metalloproteinases (MMPs) (Kelly et al, 2003). Matrix 
metalloproteinases, such as MMP-1, play an important role in normal physiologic processes, 
such as wound healing and cell migration but conversely, dysregulated expression has been 
implicated in the pathological processes associated with cancer, rheumatoid arthritis, 
9atherosclerosis and periodontitis (Saarialho-Kere, 1999; Reed, 2000; Egeblad, Werb, 2002; 
Vincenti, Brinckerhoff, 2002; Nikkari et al, 1995; Kubota, 1996). 
In addition to resident fibroblasts, a dense infiltration of mononuclear cells, including 
monocyte-derived macrophage have been observed in periodontitis affected gingival tissues. 
These cells play a key role in host defense although exuberant macrophage activity has been 
implicated in periodontal pathology (Genco RJ, Slots J. 1984; Uden CE et al, 1998; Zappa U 
et al, 1991; Nares et al, 2009). First identified as a major component of host defense by Eli 
Metchnikoff approximately 100 years ago, monocytes and macrophages originate as 
pleuripotent stem cells that differentiate into monoblast precursors in the bone marrow. Adult 
peripheral blood monocyte counts in adults are normally between 1 and 6 percent of the total 
white blood cell count (300-700 cells/µl of blood) and rarely exceed 10 percent. Monocytes 
circulate in the bloodstream and eventually emigrate and take up residence in virtually every 
tissue in the body where they differentiate into morphologically and functionally 
heterogeneous effector cells such as macrophages, microglia, Kupffer cells, dendritic cells 
and osteoclasts (Hume et al, 2002). Macrophages are typically large cells measuring between 
10-30 mm in diameter (Junqueira, Basic Histology, 1988) with a round or indented nucleus 
located eccentrically. In addition, most macrophages have a well-developed Golgi apparatus, 
abundant endocytotic vacuoles, lysosomes, and phagolysosomes, and a plasma membrane 
covered with ruffles or microvilli. Interestingly, I have noted that these pleomorphic cells 
adapt to culture conditions and attachment substrate in-vitro forming morphologically-
distinct phenotypes such as small, dendritic-like cells to large and round cells (Figure 5). 
These findings may reflect upon their functional capacity in-vivo within different tissues and 
substrates.  
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Macrophages play a critical role in innate (phagocytosis, pinocytosis) and adaptive 
(antigen presentation, Th cytokine production) immunity (Nares and Wahl, 2005).  In innate 
immunity to infectious pathogens, macrophages are among the earliest responders, 
recognizing pathogens through a family of toll-like (TLR) and scavenger receptors that 
engage signals driving host defense resulting in activation and secretion of proinflammatory 
mediators. Similarly, products from antigen-activated Th1 lymphocytes, most notably IFN-γ
interact with its receptor on these cells and drive changes associated with an activation 
phenotype, referred to as M1 (classically activated) macrophages, whereas Th2 cytokines, 
including IL-4 and/or IL-10, alternatively activate macrophages (M2) and may dampen its 
function. Further, the proinflammatory macrophage phenotype identified by the surface 
antigen, 27E10, initiate the recruitment and degranulation of neutrophils, and facilitate 
immune mediated inflammatory tissue destruction (Clark, 1988; Andreesen, 1990). These 
cells are associated with the production of proinflammatory cytokines, such as IL-1, IL-6, 
and TNF-α commonly seen in gingival tissues of chronic periodontitis patients (Clark, 1988; 
Andreesen, 1990). A second phenotype, the reparative and proliferative macrophage, is 
identified by the antigen RM3/1 (CD163), and is associated with the production of 
polypeptide growth factors including TGF-β and PDGF-B.  These cells are identified in 
tissues following the resolution of pathologic processes and during the reparative phase 
following periodontal treatment (Ross, 1986; Martin, 1992). Studies indicate that this 
phenotype is present at higher levels within gingival specimens from DIGO subjects 
compared to the 27E10 phenotype (Iacopino et al, 1997). Nurmenniemi (2002) further 
demonstrated that this macrophage phenotype was present in significantly higher numbers 
from overgrowth biopsies derived from immunosuppressine agents relative to healthy 
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controls. This same study also reported elevated numbers of 27E10-positive macrophages in 
CSA-, CSA + nifedipine and nifedipine-induced gingival overgrowth (Nurmenniemi et al 
2002).
Macrophages are one of the few cell types that can migrate among and between body 
compartments. Consequently, their capacity to degrade basement membranes and other 
extracellular matrices is accomplished by the production of collagenolytic, elastinolytic and 
gelatinolytic hydrolases (Takemura and Werb, 1984). These cells are also widely recognized 
as the principle mediators of connective tissue turnover, maintenance and repair (Riches, 
1988; Andreesen et al, 1990; Messadi and Bertolami, 1991; Martin et al, 1992; Kreutz et al,
1992; Wikesjo et al, 1992). Indeed, the macrophage receives, amplifies, and transmits signals 
to fibroblasts, endothelial cells, and vascular smooth muscle cells by producing 
proinflammatory cytokines, matrix mettaloprotienases (MMPs) and their inhibitor (TIMPs) 
along with peptide growth factors, such as platelet-derived growth factor (PDGF), 
transforming growth factor (TGF), and basic fibroblast growth factor (bFGF) (Shimokado, 
1985).
  Production of growth factors has been reported to be instrumental in facilitating 
neovascularization and synthesis of connective tissue proteins that comprise the ECM.  
Platelet derived growth factor (PDGF) is a dimeric polypeptide consisting of two related 
peptide chains, PDGF-A and PDGF-B, found in the alpha granules of platelets and is 
secreted by numerous cells including macrophages, endothelial cells and fibroblasts. 
Biological activity has been noted for the PDGF-AA, PDGF-BB and PDGF- AB isoforms.  
PDGF-B is a chemoattractant and mitogen for fibroblasts capable of inducing production of 
12
glycosaminoglycans, proteoglycans, fibronectin and collagen (Raines, 1990, Pierce, 1991, 
Hosgood, 1993) and has also been shown to induce angiogenesis via growth and proliferation 
of endothelial and smooth muscle cells (Raines, 1990). MMP activity on the other hand is 
characteristic and instrumental in the maintenance of connective tissue homeostasis (Domeij 
et al, 2006). Therefore, it is possible that drugs inducing gingival overgrowth not only 
dysregulate expression of growth factors that trigger collagen production, but also 
dysregulate expression of matrix-degradating enzymes and/or inhibitors. Indeed numerous 
studies have identified upregulation of PDGF-B, fibroblast growth factor-2 (FGF-2), 
transforming growth factor-β (TGF-β), and connective tissue growth factor (CTGF) 
(Williamson et al, 1994; Nares et al, 1996; Plemons et al, 1996; Saito et al, 1996; Dill and 
Iacopino, 1997; Iacopino et al, 1997; Atilla and Kutukculer, 1998; Sasaki and Maita, 1998; 
Hong et al, 1999; Myrillas et al, 1999; Buduneli et al, 2001; Uzel et al, 2001; Cotrim et al,
2002), and while findings regarding MMP expression have yielded conflicting results (Tuter 
et al, 2002; Atilla et al, 2001; Emingil et al, 2008; Sonmez et al, 2008;), numerous studies 
have identified dysregulation of MMP expression in DIGO (Kanno et al, 2008; Sukkar et al,
2007; Sakagami et al, 2006;   Dannewitz et al, 2006; Kato et al, 2006, 2005; Gagliano et al,
2005, 2004;  Hyland et al, 2003; Cotrim 2002; Silva et al, 2001; Yamada et al, 2000; Bolzani 
et al, 2000; Kataoka et al, 2000; Sugano et al, 1998). 
Justifiably, most of the in-vitro studies have been performed on gingival fibroblasts 
while very few have attempted to investigate growth factor and MMP/TIMP expression in 
immune cells. It has been previously demonstrated that a significant increase in PDGF-B 
production in the gingival tissues of both PHT- and CSA-induced gingival overgrowth 
compared with healthy individuals (Iacopino et al, 1997; Nares et al, 1996).  The cellular 
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source of PDGF-B in–vivo was identified to be RM3/1-positive macrophages (Iacopino et al,
1997). More recently, we demonstrated that pretreatment of human macrophage cultures with 
phenytoin or its metabolite HPPH, prior to challenge with purified LPS from the periodontal 
patholgen, Aggregatibacter actinomycetemcomitans, blunted supernatant levels of MMP-1, 
MMP-2, MMP-3, MMP-9, and TIMP-1 compared with macrophages exposed to LPS alone 
suggesting that both phenytoin and its reactive metabolites may inhibit the ability of these 
cells to contribute to turnover of ECM in gingival tissues (Serra et al, in preparation). In 
support, Zhou (1996) reported that the cytochrome P450 enzymes, CYP1A1, CYP1A2, 
CYP2C9, CYP2E1 and CYP3A4 were abundantly present in gingival microsomes of biopsy 
samples taken from phenytoin-induced gingival overgrowth suggesting that reactive 
phenytoin metabolites such as HPPH may indeed form locally within gingival tissues. This is 
important given the prominent role of plaque and gingival inflammation that attract 
macrophages to affected tissues. Thus, these cells not only secrete growth factors 
instrumental in collagen synthesis upon exposure to CSA and PHT, their ability to degrade 
exuberant collagen production via MMP production is significantly blunted by PHT and its 
metabolite, HPPH (Serra et al, in preparation).
Tumor necrosis factor α (TNF-α), secreted by numerous cells including monocytes 
and macrophages has been shown to induce cellular proliferation (Sugarman et al, 1985), 
induce fibroblast production of ECM and inhibit phagocytosis of collagen by gingival 
fibroblasts resulting in collagen accumulation (Chou et al, 1996). Additionally, it has been 
shown that TNF-α induces IL-1β (Yucel-Lindberg T, 1995), IL-6, TGF and prostaglandin E2
production in gingival fibroblasts (Modeer et al, 1992) all of which may positively impact 
ECM accumulation in-vivo. Conversely, TNF-α also has been reported to inhibit collagen 
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synthesis (Solis-Herruzo et al, 1988) and increase (MMP) synthesis by these same gingival 
fibroblasts (Domeij et al, 2002), which contributes to gingival breakdown. It remains unclear 
how these two contrasting functions are mediated by TNF-α (Kato et al, 2006), but the 
answer may lie in the relative concentration of TNF-α in the gingival tissues. TNF-α 
concentrations have been reported to range from 1 to 50 ng/ml in chronically inflamed sites 
(Stashenko et al, 1991), and it has been demonstrated that low levels of TNF-α (<10 ng/ml) 
induce collagen accumulation and fibrosis, whereas elevated levels result in collagen loss 
(Chou et al, 1996). Therefore, it appears that gingival fibroblasts exposed to lower levels of 
TNF-α may be at a higher risk for dysregulation than those exposed to higher levels. Further, 
spontaneous gingival overgrowth has been reported in patients with long standing low grade 
chronic gingival inflammation (Kato et al, 2006). Our in-vitro studies demonstrate that 
purified LPS from Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis
stimulate human macrophages to produce significantly higher levels of TNF-α compared to 
untreated controls (Nares et al, 2009; Serra et al, in preparation). However, supernatant levels 
of TNF-α were significantly decreased in cultures pretreated with PHT, prior to challenge 
with LPS. This blunted production of TNF-α by inflammatory cells may tip the balance 
towards collagen accumulation and fibrosis rather than turnover.
IL-6 is a pleotrophic cytokine produced by numerous cells in-vivo known to enhance 
proliferation and regulation of collagen and glycosaminoglycan synthesis by fibroblasts 
(Wahl, 1985). Studies have reported elevated levels of IL-6 in-vitro (Chae et al, 2006; 
Modéer et al, 2000; Morton et al, 1999) and in-vivo (Myrillas et al, 1999; Williamson et al, 
1994; Rostock et al, 1986) suggesting that dysregulated expression of IL-6 is associated with 
DIGO. Moreover, phenytoin has been reported to increase both IL-6 and IL-8 production by 
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gingival fibroblasts (Modéer et al, 2000). This effect was enhanced by IL-1β implying that 
the inflammatory milieu present in DIGO provides a positive feedback mechanism for IL-6 
expression. Our studies demonstrate that unlike the fibroblast, phenytoin and its metabolite 
do not stimulate production of IL-6 compared to untreated controls in the absence of LPS. 
However, unlike TNF-α, supernatant IL-6 levels remain significantly elevated to levels 
comparable to LPS-only treated cells in the presence of these agents (Serra et al, in 
preparation). Thus gingival macrophages may contribute to elevated IL-6 levels in-vivo
enhancing fibroblast proliferation and collagen synthesis. 
Conclusion
Drug-induced gingival overgrowth is a multifactorial condition widely 
recognized clinically but not entirely understood pathophysiologically. DIGO occurs in 
approximately half of patients taking phenytoin and is closely correlated with a history of 
inflammation associated with inadequate plaque control. It is understood that gingival tissue 
homeostasis is maintained by a delicate balance of ECM production and degradation by a 
collective group of resident (fibroblasts) and transient cells (e.g. macrophages).  As such, an 
increasing body of evidence now implicates the macrophage in the pathophysiology 
underlying DIGO. These cells differentiate from blood monocytes and are attracted to sites of 
inflammation such as affected gingival tissues. Further, the presence of cytochrome P450 
enzymes implies that reactive metabolites of phenytoin such as HPPH, may form locally 
within gingival tissues exposing such cell to these toxic agents. Combined, these agents may 
steer extravasating monocytes to differentiate towards the reparative/proliferative RM3/1 
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macrophage phenotype with a concomitant increase in PDGF-B secretion and a decrease in 
MMP production and dysregulated cytokine expression locally. This functionally-altered 
macrophage state may tip the balance of ECM homeostasis towards one of collagen 
production and decreased turnover.
Phenytoin and its Metabolite, 5-(p-Hydroxyphenyl-), 5-
Phenylhydantoin, Decrease Supernatant Levels of Matrix-
Metalloproteases in the Human Macrophage: Implications for 
Drug-Induced Gingival Overgrowth
Introduction
Drug-induced gingival overgrowth (DIGO) is widely recognized as a common 
unwanted sequelae associated with a variety of medications. Among these, the antiepileptic 
agent, phenytoin (Dilantin), has been reported to induce DIGO in approximately 50% of 
patients taking this medication (Academy Report on Drug Induced Gingival Enlargement 
2004, Neville et al,2002). Phenytoin (PHT) is a hydantoin-derivative anticonvulsant that 
exerts its anticonvulsant properties by stabilizing neuronal cell membranes to the action of 
sodium, potassium, and calcium. The drug also affects the transport of calcium across cell 
membranes and decreases the influx of calcium ions across membranes by decreasing 
membrane permeability and blocking intracellular uptake (Pincus, 1972). Further, one of the 
metabolites of phenytoin, 5-(4-hydroxyphenyl-), 5-phenylhydantoin (HPPH), may also 
contribute to the pathogenesis of DIGO (Lin et al, 2008; Ieiri et al, 1995).  Zhou (1996) 
examined the metabolism of PHT by gingival microsomes and reported that the cytochrome 
P450 enzymes, CYP1A1, CYP1A2, CYP2C9, CYP2E1, and CYP3A4 were abundantly 
present within gingival specimens. This suggests that reactive PHT metabolites may form 
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locally within gingival tissues exposing resident and inflammatory cells to these toxic agents 
triggering and/or sustaining gingival overgrowth. 
While most studies have focused on the role of the fibroblast (Seymour el, 2000, 
1996; Abergel et al, 1984; Hassell et al, 1976), it is likely that other cells contribute to the 
pathogenesis of DIGO. In particular, tissue macrophages, present in elevated numbers within 
gingival tissues, possibly in response to accumulation of the plaque biofim (Penarrocha-
Diago et al, 1990; Iacopino et al 1997), may play a role in pathogenesis. These long-lived 
multifaceted cells, strategically poised along portals of entry, perform numerous functions of 
vital importance to the host. Macrophages are TLR+ cells that respond rapidly to microbial 
infection as part of the innate arm of the immune system and aid in the transition to and the 
propagation of the adaptive immune response (Nares and Wahl, 2005). The macrophage is 
also recognized as the major mediator of connective tissue turnover, maintenance and repair 
(Riches, 1988; Andreesen et al, 1990; Messadi and Bertolami, 1991; Martin et al, 1992; 
Kreutz et al, 1992; Wikesjo et al, 1992), it receives, amplifies, and transmits signals to 
fibroblasts, endothelial cells, and vascular smooth muscle cells by producing pro-
inflammatory cytokines, such as IL-1, IL-6 and TNF-α, as well as MMPs, TIMPs, and 
peptide growth factors, such as platelet-derived growth factor (PDGF), transforming growth 
factor (TGF), and basic fibroblast growth factor (bFGF) (Shimokado, 1985).  However
beyond these essential functions, the macrophage has been implicated in the evolution of 
pathological processes. Previous related studies indicate that the macrophage responds 
rapidly and aggressively to LPS from periodontal pathogens by generating chemokines, 
proteases, and cytokines capable of driving T-helper cell lineage polarization without 
evidence of corresponding immunosuppressive pathways (Nares et al, 2009, Moutsoupolous 
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et al, in preparation). Further studies have also demonstrated that the clinical presentation of 
PHT-induced gingival overgrowth is associated with specific macrophages phenotypes 
expressing IL-1β and PDGF-B (Iacopino et al, 1997; Nares et al, 1996) suggesting that these 
cells contribute to the pathogenesis of DIGO.  These findings highlight their prominent role 
in host defense and conversely, progressive tissue pathogenesis evident in periodontal 
inflammation and gingival overgrowth.
Along with the production of growth factors, cytokines and chemokines, activated 
macrophages are also capable of producing MMPs and TIMPs. As tissue homeostasis 
requires the proper balance of metabolism and catabolism of the extracellular matrix, it is 
possible that macrophage-derived cytokines, MMPs and TIMP levels are altered in response 
to PHT and HPPH. Here I investigated the effects of these agents on expression of MMPs 
(MMP1, MMP2, MMP3, MMP9, MMP12), TIMPs (TIMP1, TIMP2, TIMP3, TIMP4) and 
proinflammatory cytokines (TNF-α, IL-6) in human monocyte-derived macrophages and 
report that indeed, these agents significantly impact macrophage function and their ability to 
regulate MMP and cytokine levels in response to periodontopathic LPS. 
Materials and Methods
Monocyte Isolation and Differentiation into Macrophages 
Peripheral blood mononuclear cells were obtained from buffy coats (Oklahoma Blood 
Institute, Oklahoma City, OK) derived from healthy donors by density gradient 
centrifugation using Ficoll-paque (Amersham, Uppsala, Sweden). Six independent cultures 
were obtained from 6 independent donors. While several studies have shown a gender 
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component to DIGO, with males being three times more likely to develop this than females 
(Academy Report on Drug Induced Gingival Enlargement 2004; Seymour et al, 2000; Ellis et 
al, 1999), limitations within this investigation did not allow me to discriminate between 
these.  Monocytes were isolated using CD14 MicroBeads (Miltenyi Biotec, Auburn, CA) 
according to manufacturer’s instructions and cultured as previously described (Nares et al,
2009; Peng et al, 2007). Briefly, isolated monocytes were plated onto duplicate 12-well tissue 
culture-treated plates (BD Biosciences, San Jose, CA) at a density of 5 x 105 cells/cm2 in 
serum-free DMEM (Cellgro, Manassas, VA) containing 50 µg/mL gentamicin (Sigma, St. 
Louis, MO) at 37 C, 5% CO2 to promote monocyte attachment. After 2 hours, heat-
inactivated fetal bovine serum (FBS, Invitrogen, Carlsbad, CA) was added to a final 
concentration of 10%. Cells were >95% CD14+ as determined by FACS analysis (data not 
shown) prior to culture. 
Macrophage Stimulation 
After 5 days, the media and non-adhered cells were removed and replaced with 
complete media (DMEM, L-glutamine, gentamycin, 10% FBS). Cultures were incubated at 
37°C and 5% CO2 with media replacement every 2 days. Experiments were initiated upon 
confirmation of macrophage differentiation after 7 days in culture (Nares, et al, 2009, Nares 
and Wahl, 2005, Peng et al, 2007). Macrophages were used between day 7 and 10 and 
pretreated for 1 hour with either: 1) 15µg/mL of PHT-Na+ (Sigma), (serum levels), (Vajda, 
1970; Hvidberg and Dam, 1976; Eadie, 1976); 2) 50µg/mL phenytoin-Na+ (high dose); 3) 
15µg/mL phenytoin metabolite (Sigma), [5-(4’-hydroxyphenyl), 5-phenylhydantoin, HPPH];
or 4) 50µg/mL HPPH. Untreated cells served as control cultures. Stock solutions of PHT-
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Na+ (150 mg/mL) were prepared in sterile deionized water while HPPH (150mg/mL) 
solutions were prepared in dimethyl sulfoxide (DMSO). Each stock solution of each agent 
was further diluted prior to use. The total concentration of DMSO in cultures was always less 
than 0.05%. Concentrations less than 0.1% have been determined not to affect cellular 
viability and function (Chen et al, 2005; Rival et al, 2004).  
To induce MMP expression, macrophages were challenged with 100ng/mL purified 
LPS in serum-free media from Aggregatibacter actinomycetemcomitans (A.a.), serotype b, 
strain Y4, a kind gift from K. Kirkwood (University of South Carolina), for either 4 hours 
(measure mRNA gene expression) or 24 hours (measure protein levels). Isolation and 
purification of A.a. LPS has been previously described (Rossa et al, 2007).  A.a. was selected 
because it is known to, not only colonize periodontal pockets, but also gain access to the 
circulation through the gingival tissues (Spahr et al, 2006; Scheinkein et al, 2000). This 
pathogen has also been shown to produce LPS which induces macrophages to produce TNF-
α and MMPs (Zadeh et al, 2000). This concentration of  LPS was selected based upon results 
from our pilot study (data not shown), investigating TNF-α and MMP production in response 
to 1ng/mL, 10ng/mL, 100ng/mL, and 1000ng/mL of A.a.  For both measures, an asymptotic 
response was observed at the 100ng/mL concentration, which corresponds with optimal 
dosage.
Real Time-PCR
After 4 hours of LPS stimulation (5 hours PHT or HPPH exposure), the media was 
removed and cells immediately lysed using 1 mL Tri Reagent (Invitrogen) and total RNA 
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isolated according to manufacturer’s instructions. This time point was selected based upon
previous findings by Nares (unpublished, data not shown) which demonstrate a general down 
regulation of gene expression at 4 hours with a rebound effect noted at 12 hours.  Total RNA
concentration was adjusted to 1μg/mL, and cDNA was synthesized using a random hexamer 
primer (Invitrogen) and Superscript II enzyme (Invitrogen) in a 25µL reaction mix at 42 C 
for 1 h. The cDNA was quantified using a NanoDrop, and 1µg of each RT product was 
amplified by real-time PCR in a 20µL reaction mix on an ABI 7500 Real Time PCR System 
(Applied Biosystems, Foster City, CA). Amplification was performed with TaqMan on-
demand gene expression assays for MMP1 (Assay ID: Hs00233958 m1), MMP9 (Assay ID: 
Mm00600164 g1), TIMP1 (Assay ID: Hs00355335 g1) from Applied Biosystems. GAPDH 
was used for normalization control. Amplification parameters and conditions were set by the 
manufacturer. Data were analyzed using the 2-ΔΔCT method (Livak and Schmittgen, 2001) 
and results reported as fold changes. 
MMP, TIMP Protein Assay
Quantification of supernatant MMP1, MMP2, MMP3, MMP9, MMP12 and TIMP1, 
TIMP2, TIMP3 and TIMP4 were assayed using the Fluorokine MAP Multiplex Human 
MMP Panel (R & D, Minneapolis, MN) and the Human TIMP Fluorokine MAP 4-plex Kit 
(R & D) respectively, on the Luminex 100 System (Luminex Co., Austin, TX). After 24 
hours, the media was collected, spun at 12,000 x g, transferred to fresh tubes and stored at     
-80° C until further use. Six independent experiments were performed from cells derived 
from six different donors. The assays were performed in 96-well plates, as previously 
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described (Nares et al, 2009). For MMP determination, microsphere beads coated with 
monoclonal antibodies against the five different target analytes were added to the wells. For 
TIMP determination, microsphere beads coated with monoclonal antibodies against the four
different target analytes were added to the wells of a separate plate. To remain below the 
upper level of quantitation, samples containing LPS were diluted 10-fold prior to analysis. 
This dilution factor was based on our previous pilot studies (data not shown). Samples and 
standards were pipetted into wells, incubated for 2 hours with the beads then washed using a 
vacuum manifold (Millipore Corporation). Biotinylated secondary antibodies were added and 
incubation for 1 h. The beads were then washed and incubated for an additional 30 minutes 
with streptavidin conjugated to the fluorescent protein, R-phycoerythrin (streptavidin/R-
phycoerythrin). The beads were washed and analyzed (a minimum of 50 per analyte) using 
the Luminex 100 system. The Luminex 100 measures the amount of fluorescence associated 
with R-phycoerythrin, reported as median fluorescence intensity of each spectral-specific 
bead allowing it to distinguish the different analytes in each well. The concentrations of the 
unknown samples (antigens in macrophage supernatants) were estimated from the standard 
curve using a third-order polynomial equation and expressed as pg/ml after adjusting for the 
dilution factor. Samples below the detection limit of the assay were recorded as zero. The 
minimum detectable concentrations for the assays were as follows: MMP-1: 4.4 pg/ml, 
MMP-2: 25.4 pg/ml, MMP-3: 1.3 pg/ml, MMP-9: 7.4 pg/ml, TIMP-1: 1.54 pg/ml, TIMP-2: 
14.7 pg/ml, TIMP-3: 86 pg/ml and TIMP-4: 1.29 pg/ml. All values were standardized for 
total protein using the Bradford assay (Pierce, Thermo Scientific, Rockford, IL) according to 
manufacturer’s instructions. Briefly, culture supernatants were mixed with assay reagent and 
incubated for 10 minutes at room temperature in 96 well plates. BSA (Invitrogen) was used 
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as a standard. The absorbance at 595 nm was read using a SpectraMax M2 microplate reader 
(Molecular Devices, Sunnyvale, CA). Control values were arbitrarily used as a baseline 
measure. The ratio, (control)/(supernatant protein value) was used to normalize each sample 
based on total protein. 
Cytokine Assay 
After 24 hours, supernatants were collected and supernatant levels of TNF-α 
and IL-6 determined by ELISA (RayBiotech, Norcross GA) according to manufacturer
instructions. The absorbance at 450 nm was read using a SpectraMax M2 microplate reader 
(Molecular Devices) with the wavelength correction set at 550 nm. The rated sensitivities of 
the commercial ELISA kits was 15 pg/mL for TNF-α and 6 pg/ml for IL-6. Values were 
standardized for total protein using the Bradford assay as described above.
Cell Viability
Viability of macrophages was evaluated using the CellTiter 96 AQueous One 
Solution Cell Proliferation Assay [3-(4,5- diethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium,inner salt, MTS] assay according to the manufacturer’s 
protocol (Promega, Madison, WI). This colorimetric method can be used to determine the 
number of viable cells in proliferation or to evaluate cytotoxicity. Briefly, macrophages were 
cultured in triplicate in 96-well plates and treated with PHT, HPPH and LPS as described 
above. Unstimulated cells served as control cultures. After 24 h, the cells were incubated 
25
with MTS for 2 h at 37 C, 5% CO2. The absorbance was read at 490 nm using a SpectraMax 
M2 microplate reader. 
Statistics 
Data were analyzed using a hierarchical multiple regression approach relative to LPS, 
drug and dose.  The first tier sought to confirm the biology and establish the validity of the 
positive control, LPS vs the negative control group.  The second tier of this analysis is aimed 
at determining whether or not PHT or HPPH have an effect on this biologic response.  
Finally, the third tier sought to contrast dose response and compare one drug with another.
Data were expressed as mean ± SEM and compared using a two-tailed Student's t test for 
correlated samples (GraphPad Prism, GraphPad Software, La Jolla, CA). Results were 
considered statistically significant at p<0.05.
RESULTS
PHT and HPPH Inhibit LPS-Induced Supernatant Levels of MMP-1, MMP-2, MMP-3, 
MMP-9, and TIMP-1 in a Dose-Dependent Manner 
Previous studies have determined that PHT plasma levels of 10-20mg/mL are usually 
necessary to effectively maintain effective seizure control (Vajda, 1970; Hvidberg and Dam, 
1976; Eadie, 1976). Thus, the concentrations used in our study represent therapeutic as well 
as elevated levels of PHT permitting the evaluation of dose on MMP and TIMP production. 
To rule out the possibility that differences in supernatant levels of these readouts were due to 
decreased cell viability, I performed a viability assay on cells cultured in each condition. No 
significant differences were noted in viability in cells exposed to LPS and either dose of PHT 
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and HPPH or LPS/PHT and LPS/HPPH as determined by MTS assay (data not shown). 
Further, I standardized the results of each analyte to total protein concentration for each 
condition using a Bradford assay. As expected, A.a. LPS induced a marked increase in 
supernatant MMP-1, MMP-3, MMP-9, and TIMP-1 levels in each of the six independent 
cultures after a 24-hour exposure (Figure 6 – 9). In contrast, neither PHT nor HPPH induced 
any significant change in supernatant levels of these proteins compared to untreated cultures. 
However, pretreatment of macrophages with PHT or HPPH prior to LPS challenge was 
associated with reduced supernatant levels of MMP-1, MMP-3, MMP-9 and TIMP-1 when 
compared with macrophages exposed to LPS alone. A dose-dependent effect was noted as 
pretreatment with 15µg/mL of PHT prior to LPS challenge reduced MMP-1 and MMP-3 
(p<0.01) levels to a lesser extent than that noted for 50µg/mL (MMP-1, p<0.05; MMP-3, 
p<0.001) (Figure 6 – 9). At this concentration, MMP-9 and TIMP-1 levels were also 
significantly reduced (p<0.01; p<0.05, respectively).  At 50µg/mL of HPPH, MMP-9 
(p<0.05) and TIMP-1 (p<0.05) were significantly reduced compared to LPS only. 
Interestingly, HPPH but not PHT was associated with reduced levels of MMP-2 compared to 
LPS only, but this relationship was not significant. MMP-12 and TIMPs-2-4 remained below 
levels of detection in all groups and cultures (data not shown). 
Supernatant Levels of TNF-α but not IL-6 are Decreased in Response to PHT 
At 24 hours, supernatant levels of TNF-α and IL-6 were significantly increased by 
A.a. LPS compared to untreated controls. Similar to MMP and TIMP levels, no significant 
increases in TNF-α and IL-6 was noted in culture supernatants exposed to either 15 or 
50µg/mL PHT and HPPH compared to untreated cells. However, macrophage cultures 
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pretreated with 50µg/mL PHT then challenged with A.a. LPS showed a significant (p<0.05) 
decrease in TNF-α levels compared to LPS only treated cultures. No difference was noted for 
15µg/mL of PHT or HPPH at either concentration (Figure 13). Regardless of dosage, 
pretreatment with PHT and HPPH prior to LPS challenge had no significant effect (p>0.05) 
on supernatant IL-6 levels compared to LPS only treated cultures. 
PHT Inhibit LPS-Induced MMP-9 and TIMP-1 mRNA in a Dose-Dependent Manner at 
4 hours
At 4 hours, MMP-9 mRNA was markedly upregulated in macrophage cultures 
challenged with A.a. LPS. Exposure of cells to 15µg/mL of PHT or HPPH increased MMP-9 
mRNA levels relative to controls. However at 50µg/mL of PHT or HPPH, MMP-9 mRNA 
levels remained near control levels. Strikingly, pretreatment of cells with either PHT or 
HPPH prior to LPS challenge resulted in downregulation of MMP-9 mRNA levels to that 
comparable to control cultures (Figure 11). TIMP-1 mRNA was downregulated in LPS-only 
cultures as well as PHT and HPPH at either dose. When pre-incubated with these agents then 
challenged with LPS, TIMP-1 mRNA levels returned to near control levels. Interestingly, the 
combination of 15µg/ml HPPH plus LPS upregulated TIMP-1 mRNA two-fold compared to 
controls (Figure 12).
DISCUSSION
Macrophages are involved in a remarkably diverse array of homeostatic processes of 
vital importance to the host. In addition to their critical role in innate immunity, these cells 
help orchestrate immune responses within tissues at sites of antigen deposition and/or 
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pathogen invasion by processing and presenting antigen in the context of MHC class II 
molecules to effector cells, as well as amplifying the immune response via the production of 
proinflammatory mediators, cytokines and chemokines (Nares and Wahl, 2005). 
Macrophages are also widely recognized as ubiquitous mediators of cellular turnover and 
maintenance of extracellular homeostasis (Riches, 1988; Andreesen et al, 1990; Messadi and 
Bertolami, 1991; Martin et al, 1992; Kreutz et al, 1992; Wikesjo et al, 1992). However, 
beyond their essentiality in immunity and tissue homeostasis, the macrophage has also been 
implicated in the evolution of periodontal pathological processes including periodontal 
disease and DIGO (Nares et al, 2009; Mousopolous et al, in preparation; Trackman et al,
2004; Nurmenniemi PK et al, 2002; Iacopino et al, 1997; Nares et al, 1996). This 
investigation posited that macrophage-derived expression of pro-inflammatory cytokines, 
MMPs and/or TIMP expression is blunted upon exposure to PHT and/or HPPH hindering the 
ability of these cells to contribute to the fibroblast-mediated degradation of exuberant ECM 
proteins seen in DIGO. Since plaque-induced gingival inflammation exacerbates the 
manifestations of PHT-induced DIGO (Majola et al, 2000), I exposed macrophage cultures to 
LPS from the periodontal pathogen Aggregatibacter actinomycetemcomitans and examined 
levels of proinflammatory cytokines, MMPs and TIMPs. As expected, A.a. LPS challenge 
markedly increased supernatant levels of TNF-α, IL-6, MMP-1, MMP-3, MMP-9, as well as 
TIMP-1, in agreement with previous studies (Bodet et al, 2006; Woo et al, 2004; Zhang et al,
1998). This highlights the responsiveness of these cells to toxins from periodontopathic 
organisms and confirms the capability of these cells to produce matrix-degradating enzymes. 
MMP-1 is recognized as an important mediator of connective tissue remodeling 
reported to be present at high concentrations in inflamed gingiva (Ryan and Golub, 2000). 
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Sonmez (2008) recently compared MMP-1 levels between gingival fibroblasts derived from 
patients with cyclosporine-A (CSA)-induced gingival overgrowth to those derived from 
patients taking CSA but without overgrowth. This study found no difference in MMP-1 
expression between the groups although no comparisons were made between gingival 
biopsies derived from periodontally-healthy subjects not taking CSA. Sukkar (2007) reported 
that fibroblasts derived from CSA-induced gingival overgrowth produced significantly lower 
levels of MMP-1 than fibroblasts derived from healthy subjects. Further, when fibroblast 
cultures were challenged with interleukin-1 and oncostatin M, a significant increase in the 
upregulation of MMP-1 was noted which was blunted when cyclosporin or nifedipine were 
added to the cell cultures (Sukkar et al, 2007). In our study, supernatant MMP levels,
including MMP-1 from human macrophages did not demonstrate any difference in response 
to PHT and HPPH at either dose compared to untreated cultures. However, when cultures 
were pretreated with these agents prior to LPS challenge, the extent of the drug-induced 
blunting of MMP levels became evident. After 24 hours, supernatant levels of several MMPs 
were significantly decreased relative to LPS-only cultures in a dose-dependent manner 
suggesting that local elevations of PHT and HPPH concentrations within gingival tissues 
mitigate the macrophage’s ability to degrade ECM proteins by limiting its natural response to 
produce metalloproteinases. Such a dose response is consistent with other studies which have 
demonstrated, not only a similar effect on MMP-1 and MMP-3 at the protein and mRNA 
level (Sugano et al. 1998, Thomason et al. 1998, Bolzani et al. 2000, Kataoka et al. 2000, 
Yamada et al. 2000, Hyland et al. 2003), but also that a threshold of serum concentration of 
CSA helps to govern this mechanism (McGaw et al. 1987; Pan et al. 1992; Pernu et al. 
1992a; King et al. 1993; O’Valle et al. 1994; Thomason et al. 1995).  For cyclosporine, this 
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threshold is generally regarded as 200µg/L (Thomason et al, 2005). Further, expression of 
MMP-9 mRNA at 4 hours was dramatically elevated upon LPS exposure but severely 
blunted when cells were pretreated with PHT or HPPH prior to LPS challenge. Increased 
supernatant levels of MMPs at 24 hours may result from a rebound effect relative to 4 hours 
as our microarray data has demonstrated wholesale downregulation of gene expression at 4 
hours but rebounding of mRNA levels at 12 hours albeit at a suppressed level relative to 
untreated controls (Nares, unpublished findings). 
MMP activity is counteracted by the actions of TIMPs.  Here I report that exposure of 
macrophages to A.a. LPS was associated with an increase in TIMP-1 production while 
exposure to high concentration (50µg/mL) of PHT and HPPH, on the other hand, 
significantly reduced TIMP-1 levels.  This finding is consistent with in-vivo and in-vitro
evaluation of gingival fibroblasts which reported a relative reduction in MMP-1 and MMP-
8/TIMP-1 serum and GCF concentration in CSA- associated gingival overgrowth subjects 
compared with healthy controls (Eminigil et al, 2008; Gagliano et al, 2005). This reflects 
more a decrease in MMP production rather than an increase in TIMP. In fact, this 
corresponds with our findings in that supernatant levels of TIMP-1 in samples treated with 
both A.a. LPS and 50µg/mL PHT or HPPH were not significantly different relative to 
untreated controls. This demonstrates that, much like MMP expression, the exposure of
macrophages to these agents blunts the LPS-induced expression of TIMP-1 implying that the 
effects of PHT and HPPH are not necessary protein or gene specific, but merely affect a 
common pathway associated with either gene expression or post-transcriptional regulation 
associated with both MMP and TIMP production.  Regardless, the net effect is based on the 
relative ratios of MMP and TIMP.  When MMP levels decrease or TIMP levels increase, the 
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turnover of ECM diminishes, potentially leading to an exuberant accumulation of these 
proteins which may affect the macrophage’s synergistic relationship with the fibroblast in 
this pathologic process.
The overall upregulation of TNF-α observed in all samples stimulated with LPS 
corresponds with observations by Zhang et al (1998) and Saren et al (1996), who noted a 
transition to an inflammatory phenotype when provoked with similar stimuli. This 
proinflammatory cytokine has been shown to induce interstitial MMP-1 (Domeij et al, 2002; 
Birkedal-Hansen et al, 1993) and MMP-9 (Saren et al, 1996) production by fibroblasts. 
Similar to supernatant MMP levels, neither PHT nor HPPH at 15μg/mL induced TNF-α or 
IL-6 levels beyond that seen in control cultures. I did however, note a significant decrease in 
TNF-α (p<0.05) when macrophages were also exposed to high concentrations (50µg/mL) of 
PHT but not HPPH.  It is interesting to note that high concentrations of PHT suppressed
TNF-α production in our study, whereas HPPH appeared to have no effect. Metabolism of 
PHT to HPPH by gingival cytochrome P450 enzymes may override suppression of TNF-α 
locally resulting in elevated levels of this cytokine. This is of particular relevance, as TNF-α 
has been shown to stimulate fibroblast and macrophage production of MMPs, collagenases, 
gellatenases, and stromolysins as part of the mechanism for inducing increased ECM 
turnover (Zhou et al, 2009; Wang et al, 2009).  This inflammatory response may play a role 
in multiple mechanisms, including maintenance of ECM homeostasis, inflammatory cell 
migration, and tumor cell motility and invasion (Kim et al, 2009; Leber et al, 1998; Rosen et 
al, 1991).  This mechanism has been corroborated, as the addition of enteracept, a TNF-α 
inhibitor, has been shown to cause a downregulation of MMP expression (Kim et al, 2009).
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These findings are in agreement with studies by Kato (2005) which documented a 
synergistic effect of TNF-α and PHT on decreasing cellular endocytosis and degredation of 
collagen by MMPs in human gingival fibroblasts. Studies by Meikle (1989) and Brew (2000) 
have also demonstrated that PHT or TNF-α can decrease MMP but increase TIMP 
production within human gingival tissues. When combined, there was a synergistic effect as 
well as a suppression of collagen degredation.  
IL-6 is a proinflammatory cytokine secreted by numerous cells including T cells and 
macrophages in response to inflammatory or traumatic stimuli. IL-6 appears to target 
connective tissue cells such as fibroblasts by enhancing proliferation and by exerting a 
positive effect on collagen and glycosaminoglycan synthesis (Ramsden et al, 1992; Snow et 
al, 1987).  I note that A.a. LPS significantly (p <0.0001) increased IL-6 supernatant levels 
compared to control cultures. These levels remained elevated despite pretreated with PHT or 
HPPH suggesting that IL-6 primarily responds to proinflammatory stimuli but not necessarily 
to these agents. This increase in IL-6 corresponds with previous observations within gingival 
samples taken from CSA-induced (Drozdzik et al, 2004; Myrillas et al, 1999) and PHT 
induced gingival overgrowth patients (Bunduneli N et al, 2000).  Atilla (1998), further noted 
that GCF concentrations of IL-6 corresponded more with the level of gingival inflammation 
of CsA induced DIGO patients, compared with the presence of the drug itself.  They noted 
that IL-6 levels were significantly higher in inflamed CsA treated patients, not exhibiting
DIGO compared to uninflamed CsA treated patients that did exhibit DIGO.  Furthermore, the 
presence or absence of CsA appeared not to affect the overall IL-6 GCF concentration.  This 
corroborates our findings, indicating that MAC production of IL-6 is most likely linked more 
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to an inflammatory response, and has very little to do with the presence or absence of PHT or 
CsA.
In conclusion, the present results demonstrate that not only PHT but its metabolite, 
HPPH inhibit A.a. LPS-induced levels of MMPs in a dose-dependent manner and that a high 
concentration of PHT decrease TNF-α but not IL-6 levels in the human macrophage. Given 
that the degree of inflammatory infiltrate and fibrosis appears to be influenced by the quality 
of plaque control and the presence of macrophages in affected tissues, our data reveals a 
mechanism whereby PHT and HPPH preferentially dysregulate production of macrophage-
derived TNF-α but not IL-6 in response to the plaque biofilm enhancing collagen production 
by fibroblasts but without the concomitant production of MMPs in response to bacterial 
stimulation.    
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FIGURE 1
Figure 1 – Structure of PHT
Page reference – 2
35
FIGURE 2
Figure 2 – A. Normal gingival contour characterized by scalloped, knife-edged contour, pink 
color, and stippling B. PHT-induced gingival overgrowth, characterized by marginal 
erythema, lobulated papillae, and plaque accumulation.   
Page reference – 4
A
B
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FIGURE 3
Figure 3 – CSA-induced gingival overgrowth demonstrating lobulations with a pebbly-like 
appearance
Page reference – 4
Figure 4 –A. Histological appearance of normal gingiva is characterized by uniform, shallow 
rete ridge formations, mild inflammatory infiltrate, and normal ECM accumulations B. 
Gingiva from drug-induced overgrowth is characterized by elongated rete ridges,
inflammatory infiltrate, and increased accumulations of ECM.   
A
B
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FIGURE 4
Page reference – 5 
abundant 
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FIGURE 5
Figure 5 – Macrophages display morphologically distinct characteristics after 13 days in 
culture depending on plating surface.  Peripheral blood monocytes were isolated and plated 
onto culture dishes coated with either: A. collagen IV, B. fibronectin, C. collagen I, and D. 
untreated plastic.  (Nares, unpublished findings)
Page reference – 9 
A B
C D
Figure 6 – Analysis of MMP supernatant protein level was completed 
Multiplex Human MMP Panel (R & D, Minneapolis, MN) and the Luminex 100 System 
(Luminex Co., Austin, TX).  The expression was compared relative to the negative control 
(no treatment), and a positive control (
with PHT or HPPH at indicated concentrations (µg/mL) then challenged with 
where indicated. Samples were collected at 24 hours.
Legend
Compared to LPS, * p<0.05, ** p<0.01, *** p<0.001
Compared to CON, # p<0.05, ## p<0.01, ### p<0.001
Student t-test, N=6 independent donors
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FIGURE 6
using Fluorokine MAP 
A.a. LPS challenge alone).  Samples were pretreated 
A.a. LPS 
Figure 7 – LPS produces no significant effect on MMP
Control.  Furthermore, the concomitant exposure to PHT or HPPH had no significant effect 
on MMP-2 expression.  Analysis of MMP supernatant protein level was completed using 
Fluorokine MAP Multiplex Human MMP Panel (R & D, Minneapolis, MN) and the Luminex 
100 System (Luminex Co., Aus
negative control (no treatment), and a positive control (
were pretreated with PHT or HPPH at indicated concentrations (µg/mL) then challenged with 
A.a. LPS where indicated. Samples were collected at 24 hours.
Legend
Compared to LPS, * p<0.05, ** p<0.01, *** p<0.001
Compared to CON, # p<0.05, ## p<0.01, ### p<0.001
Student t-test, N=6 independent donors
40
FIGURE 7
-2 expression when compared with 
tin, TX).  The expression was compared relative to the 
A.a. LPS challenge alone).  Samples 
Figure 8 – LPS significantly increased MMP
with  50µg/mL and 15µg/mL 
levels compared to LPS-only treated cells
similar trend. Analysis of MMP supernatant protein level was completed using Fluorokine 
MAP Multiplex Human MMP Panel (R & D, Minneapolis, MN) and the Luminex 100 
System (Luminex Co., Austin, TX).  The expression was compared relative to the negative 
control (no treatment), and a positive control (
pretreated with PHT or HPPH at indicated concentrations (µg/mL) then challenged with 
LPS where indicated. Samples were collected at 24 hours.
Legend
Compared to LPS, * p<0.05, ** p<0.01, *** p<0.001
Compared to CON, # p<0.05, ## p<0.01, ### p<0.001
Student t-test, N=6 independent donors
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FIGURE 8
-3 expression. However, pretreatment of MACs 
of PHT prior to LPS challenge decreased supernatant MMP
.  The addition of 50µg/mL HPPH dem
A.a. LPS challenge alone).  Samples were 
-3 
onstrated a 
A.a.
Figure 9 – LPS significantly increased MMP
in MACs pretreated with 50µg/mL of PHT and 50µg/mL of HPPH
Analysis of MMP supernatant protein level was completed using Fluorokine MAP Multiplex 
Human MMP Panel (R & D, Minneapolis, MN) and the Luminex 100 System (Luminex Co., 
Austin, TX).  The expression was compared relative to the negative control (no treatment), 
and a positive control (A.a. 
HPPH at indicated concentrations (µg/mL) then challenged with 
Samples were collected at 24 hours.
Legend
Compared to LPS, * p<0.05, ** p<0.01, *** p<0.001
Compared to CON, # p<0.05, ## p<0.01, ### p<0.001
Student t-test, N=6 independent donors
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FIGURE 9
-9 expression.  This increase was 
prior to LPS challenge
LPS challenge alone).  Samples were pretreated with PHT or 
A.a. LPS where indicated.  
not observed 
.  
Figure 10 – LPS significantly increased TIMP
in MACs pretreated with 50µg/mL of PHT and 50µg/mL of HPPH prior to LPS challenge
Analysis of TIMP-1 supernatant protein level was completed using Fluorokine MAP 
Multiplex Human MMP Panel (R & D, Minneapolis, MN) and the Lu
(Luminex Co., Austin, TX).  The expression was compared relative to the negative control 
(no treatment), and a positive control (
with PHT or HPPH at indicated concentrations (µg/mL) then 
where indicated.  Samples were collected at 24 hours.
Legend
Compared to LPS, * p<0.05, ** p<0.01, *** p<0.001
Compared to CON, # p<0.05, ## p<0.01, ### p<0.001
Student t-test, N=6 independent donors
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FIGURE 10
-1 expression.  This increase was not observed 
minex 100 System 
A.a. LPS challenge alone).  Samples were pretreated 
challenged with 
.  
A.a. LPS 
Figure 11 – LPS produced a marked increase in MMP
however, appeared to be mitigated by the addition of PHT and HPPH, returning MMP
mRNA expression to CON levels.  Analysis of MMP mRNA was completed by Real
PCR (Taqman, Applied Biosciences, Foster City, CA).  The expression was compared 
relative to the negative control (no treatment), and a positive control (
alone).  Samples were pretreated with PHT or HPPH at indicated concentrations (µg/mL) 
then challenged with A.a. LPS where indicated.  Samples were collected at 4 hours.
Legend
Compared to LPS, * p<0.05, ** p<0.01, *** p<0.001
Compared to CON, # p<0.05, ## p<0.01, ### p<0.001
Student t-test, N=6 independent donors
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FIGURE 11
-9 expression.  This expression, 
A.a. 
-9 
-Time 
LPS challenge 
Figure 12 – LPS appeared not to have a profound impact on TIMP
However, the combination of PHT/HPPH with LPS appeared to produce a greater level of 
TIMP-1 mRNA expression.  
(Taqman, Applied Biosciences, Foster City, CA).  The expression was compared relative to 
the negative control (no treatment), and a positive control (
Samples were pretreated with PHT or HPPH at indicated concentrations (µg/mL) then 
challenged with A.a. LPS where indicated.  Samples were collected at 4 hours.
Legend
Compared to LPS, * p<0.05, ** p<0.01, *** p<0.001
Compared to CON, # p<0.05, ## p<0.01, ### p<0.001
Student t-test, N=6 independent donors
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FIGURE 12
-1 mRNA expression.  
Analysis of MMP mRNA was completed by Real
A.a. LPS challenge alone).  
-Time PCR 
Figure 13 – LPS significantly increased TNF
the addition of PHT 50µg/mL
TNF-α was determined by enzyme
Norcross GA) after 24 hour incubation.  Values were standardized for total protein using the 
Bradford assay.  The expression was compared relative to the negative control (no 
treatment), and a positive control (
PHT or HPPH at indicated concentrations (µg/mL) then challenged with 
indicated.  Samples were collected at 24 hours.
Legend
Compared to LPS, * p<0.05, ** p<0.01, *** p<0.001
Compared to CON, # p<0.05, ## p<0.01, ### p<0
Student t-test, N=6 independent donors
46
FIGURE 13
-α expression.  This increase was mitigated by 
.  HPPH had a minimal apparent effect.  Supernatant levels of 
-linked immunosorbent assay (ELISA) (RayBiotech
A.a. LPS challenge alone).  Samples were pr
.001
, 
etreated with 
A.a. LPS where 
Figure 14 – LPS significantly increased TNF
had a minimal apparent effect
immunosorbent assay (ELISA) (RayBiotech, Norcross GA) after 24 hour incubation.  Values 
were standardized for total protein using the Bradford assay.  The expression was compared 
relative to the negative control (no treatment), and a positive control (
alone).  Samples were pretreated with PHT or HPPH at indicated concentrations (µg/mL) 
then challenged with A.a. LPS where indicated.  Samples were collected at 24 hours.
Legend
Compared to LPS, * p<0.05, ** p<0.01, *** p<0.001
Compared to CON, # p<0.05, ## p<0.01, ### p<0.001
Student t-test, N=6 independent donors
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FIGURE 14
-α expression.  The addition of PHT and HPPH 
.  Supernatant levels of IL-6 was determined by enzyme
A.a. 
-linked 
LPS challenge
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